Disseminated and circulating tumor cells in gastrointestinal oncology

Bidard, François-Clément; Ferrand, François‐Régis; Huguet, F.; Hammel, Pascal; Louvet, Christophe; Malka, David; Boige, Valérie; Ducreux, Michel; Thewis, André; Gramont, Aimery de; Mariani, Pascale; Pierga, Jean‐Yves

doi:10.1016/j.critrevonc.2011.05.008

Cited by 33 publications

(22 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Uveal melanoma CTC detection was performed in each of the 40 patients included; results were as follows: no CTC detected in 28 patients (70%), one CTC detected in four patients (10%), three CTCs detected in six patients (15%), 12 CTCs detected in one patient (2.5%) and 20 CTCs detected in one patient (2.5%). The concentration of cell-free DNA in the 40 patients ranged from 0.5 to 512 ng=mL of plasma, with a median a 4.1 ng=mL.…”

Section: Ctc and Ctdna Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

Bidard

Madic

Mariani

et al. 2013

Intl Journal of Cancer

164

154

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been recently investigated in several cancer types, but their respective clinical significance remains to be determined. In our prospective study, we compared the detection rate and the prognostic value of these two circulating biomarkers in patients with metastatic uveal melanoma. GNAQ=GNA11 mutations were characterized in archived tumor tissue. Using a highly sensitive and mutation-specific bidirectional pyrophosphorolysisactivated polymerization (bi-PAP) technique, GNAQ c.626A>T, GNAQ c.626A>C and GNA11 c.626A>T copy numbers were quantified in plasma from 12 mL of blood. CTCs were detected at the same time in 7.5 mL of blood by the CellSearchV R technique. Patient characteristics and outcome were prospectively collected. CTCs (1) were detected in 12 of the 40 included patients (30%, range 1-20). Among the 26 patients with known detectable mutations, ctDNA was detected and quantified in 22 (84%, range 4-11,421 copies=mL). CTC count and ctDNA levels were associated with the presence of miliary hepatic metastasis (p 5 0.004 and 0.03, respectively), with metastasis volume (p 5 0.005 and 0.004) and with each other (p < 0.0001). CTC count and ctDNA levels were both strongly associated with progression-free survival (p 5 0.003 and 0.001) and overall survival (p 5 0.0009 and <0.0001). In multivariate analyses, ctDNA appeared to be a better prognostic marker than CTC. In conclusion, ctDNA and CTC are correlated and both have poor prognostic significance. CTC detection can be performed in every patient but, in patients with detectable mutations, ctDNA was more frequently detected than CTC and has possibly more prognostic value.Uveal melanoma is a rare cancer, with a reported incidence of two to eight new cases per million per year in Europe 1 and the United States.2 Specific mutations are found in this particular type of melanoma: >80% of uveal melanoma express mutually exclusive somatic mutations in two paralog proto-oncogenes, GNAQ 3 and GNA11, 4 which encode a-subunits of heterotrimeric G-proteins involved in the MEK-ERK signaling pathway. 5 In both genes, most mutations occur at nucleotide 626 encoding a glutamine at codon 209 (Q209). The presence of these mutations does not influence the risk of metastasis in patients. 4 Uveal melanoma metastases develop mostly in the liver through hematogenous spread of cancer cells. Despite improvement of diagnosis and treatment of the primary eye tumor, there is no effective treatment of metastatic disease; the prognosis of patients with metastatic uveal melanoma is limited, and although a few patients experience extended survival, the median overall survival (OS) following metastases detection is less than 1 year. 6 Circulating tumor cells (CTCs), which are cancer cells detected in patient blood, may correspond to cancer "seeds" that initiate metastatic relapse.7 Over the past two decades, both molecular and cytological detection techniques have

show abstract

Section: Ctc and Ctdna Detectionmentioning

confidence: 99%

“…Patient characteristics and outcome were prospectively collected. CTCs (1) were detected in 12 of the 40 included patients (30%, range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Among the 26 patients with known detectable mutations, ctDNA was detected and quantified in 22 (84%, range 4-11,421 copies=mL).…”

mentioning

confidence: 99%

Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

Bidard

Madic

Mariani

et al. 2013

Intl Journal of Cancer

164

154

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14] Nevertheless, the studies performed in colorectal cancer patients using CellSearch demonstrated a much lower yield of CTCs in this tumor type compared with breast and prostate cancer, both at baseline and in course of treatment. 15 The PCR-based assay developed by AdnaGen makes use of RT-PCR to identify putative transcripts of genes in EpCAM-positive cells isolated by a magnetic separation method. The immunomagnetic cell capture technology, combined with multiplex RT-PCR in AdnaTest may potentially allow the detection of a broad range of molecular abnormalities in CTCs supporting the design of future studies testing CTCs directed therapies.…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor cells

Raimondi

Nicolazzo

Gradilone

et al. 2014

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Le rôle des polymorphismes génétiques liés à l'hôte reste aussi incomplètement documenté. métastatique qu'en situation adjuvante [35,36]. La caractérisation moléculaire de ces cellules tumorales est actuellement un enjeu majeur pour la compréhension des étapes post-extravasation ; cette même caractérisation moléculaire des CTC est actuellement à l'étude en clinique pour déterminer si ces cellules présentent les mêmes caractéristiques moléculaires que les masses tumorales ou s'il existe des différences (lesquelles pourraient être l'objet de traitements spécifiques, par exemple l'activation significative d'une cible molé-culaire lors du passage dans la circulation).…”

Section: Déterminants Génétiquesunclassified

Biologie du processus métastatique

Bidard

Poupon

2012

Med Sci (Paris)

View full text Add to dashboard Cite

Disseminated and circulating tumor cells in gastrointestinal oncology

Cited by 33 publications

References 126 publications

Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

Circulating tumor cells

Biologie du processus métastatique

Contact Info

Product

Resources

About